Acyclovir therapy in neonates

Janet A. Englund, Courtney V Fletcher, Henry H. Balfour

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Study objective: To determine the pharmacokinetic parameters of acyclovirdisposition in neonates with renal dysfunction. Design: Prospective sequential open enroliment of neonates with presumed herpes group virus infections. Setting: Neonatal intensive care units in the greater Minneapolis-St. Paul metropolitanarea. Patients: Sixteen neonates with gestational ages between 27 and 40 weeks (median 38 weeks) were given acyclovir between days 1 and 56 of life to treat presumed herpes virus infections. Six infants were critically ill with multisystem disease, five infants had hepatic failure and underwent blood exchange transfusion, and five infants had renal failure. A mean of four (range 1 to 19) serum acyclovir concentrations per patient were measured by radioimmunoassay. Pharmacokinetic parameters were calculated from acyclovir concentrations in 46 samples from 16 patients. Measurements and main results: The pharmacokinetic disposition of acyclovirwas described as a two-compartment model. Although the ranges for acyclovir clearance and terminal elimination (t1/2β) were wide, a statistically, significant relationship was demonstrated between clearance and beta versus serum creatinine concentration. The average t1/2β for infants with serum creatinine level <1 mg/dl (88 μmol/L) was 5.0 hours, and 15.6 hours for those with serum creatinine level >1 mg/dl. Conclusions: Neonates with hepatic or renal dysfunction or young premature infants accumulate acyclovir when dosed without adjustment for organ dysfunction. Measurement of serum creatinine or creatinine clearance can be useful in the dosing of acyclovir in neonates.

Original languageEnglish (US)
Pages (from-to)129-135
Number of pages7
JournalThe Journal of Pediatrics
Volume119
Issue number1 PART 1
DOIs
StatePublished - Jan 1 1991

Fingerprint

Acyclovir
Newborn Infant
Creatinine
Pharmacokinetics
Virus Diseases
Serum
Therapeutics
Kidney
Neonatal Intensive Care Units
Liver Failure
Critical Illness
Premature Infants
Blood Transfusion
Gestational Age
Radioimmunoassay
Renal Insufficiency
Liver

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Acyclovir therapy in neonates. / Englund, Janet A.; Fletcher, Courtney V; Balfour, Henry H.

In: The Journal of Pediatrics, Vol. 119, No. 1 PART 1, 01.01.1991, p. 129-135.

Research output: Contribution to journalArticle

Englund, Janet A. ; Fletcher, Courtney V ; Balfour, Henry H. / Acyclovir therapy in neonates. In: The Journal of Pediatrics. 1991 ; Vol. 119, No. 1 PART 1. pp. 129-135.
@article{753d5bc31d5244748ac51e5e92f28199,
title = "Acyclovir therapy in neonates",
abstract = "Study objective: To determine the pharmacokinetic parameters of acyclovirdisposition in neonates with renal dysfunction. Design: Prospective sequential open enroliment of neonates with presumed herpes group virus infections. Setting: Neonatal intensive care units in the greater Minneapolis-St. Paul metropolitanarea. Patients: Sixteen neonates with gestational ages between 27 and 40 weeks (median 38 weeks) were given acyclovir between days 1 and 56 of life to treat presumed herpes virus infections. Six infants were critically ill with multisystem disease, five infants had hepatic failure and underwent blood exchange transfusion, and five infants had renal failure. A mean of four (range 1 to 19) serum acyclovir concentrations per patient were measured by radioimmunoassay. Pharmacokinetic parameters were calculated from acyclovir concentrations in 46 samples from 16 patients. Measurements and main results: The pharmacokinetic disposition of acyclovirwas described as a two-compartment model. Although the ranges for acyclovir clearance and terminal elimination (t1/2β) were wide, a statistically, significant relationship was demonstrated between clearance and beta versus serum creatinine concentration. The average t1/2β for infants with serum creatinine level <1 mg/dl (88 μmol/L) was 5.0 hours, and 15.6 hours for those with serum creatinine level >1 mg/dl. Conclusions: Neonates with hepatic or renal dysfunction or young premature infants accumulate acyclovir when dosed without adjustment for organ dysfunction. Measurement of serum creatinine or creatinine clearance can be useful in the dosing of acyclovir in neonates.",
author = "Englund, {Janet A.} and Fletcher, {Courtney V} and Balfour, {Henry H.}",
year = "1991",
month = "1",
day = "1",
doi = "10.1016/S0022-3476(05)81053-4",
language = "English (US)",
volume = "119",
pages = "129--135",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "1 PART 1",

}

TY - JOUR

T1 - Acyclovir therapy in neonates

AU - Englund, Janet A.

AU - Fletcher, Courtney V

AU - Balfour, Henry H.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Study objective: To determine the pharmacokinetic parameters of acyclovirdisposition in neonates with renal dysfunction. Design: Prospective sequential open enroliment of neonates with presumed herpes group virus infections. Setting: Neonatal intensive care units in the greater Minneapolis-St. Paul metropolitanarea. Patients: Sixteen neonates with gestational ages between 27 and 40 weeks (median 38 weeks) were given acyclovir between days 1 and 56 of life to treat presumed herpes virus infections. Six infants were critically ill with multisystem disease, five infants had hepatic failure and underwent blood exchange transfusion, and five infants had renal failure. A mean of four (range 1 to 19) serum acyclovir concentrations per patient were measured by radioimmunoassay. Pharmacokinetic parameters were calculated from acyclovir concentrations in 46 samples from 16 patients. Measurements and main results: The pharmacokinetic disposition of acyclovirwas described as a two-compartment model. Although the ranges for acyclovir clearance and terminal elimination (t1/2β) were wide, a statistically, significant relationship was demonstrated between clearance and beta versus serum creatinine concentration. The average t1/2β for infants with serum creatinine level <1 mg/dl (88 μmol/L) was 5.0 hours, and 15.6 hours for those with serum creatinine level >1 mg/dl. Conclusions: Neonates with hepatic or renal dysfunction or young premature infants accumulate acyclovir when dosed without adjustment for organ dysfunction. Measurement of serum creatinine or creatinine clearance can be useful in the dosing of acyclovir in neonates.

AB - Study objective: To determine the pharmacokinetic parameters of acyclovirdisposition in neonates with renal dysfunction. Design: Prospective sequential open enroliment of neonates with presumed herpes group virus infections. Setting: Neonatal intensive care units in the greater Minneapolis-St. Paul metropolitanarea. Patients: Sixteen neonates with gestational ages between 27 and 40 weeks (median 38 weeks) were given acyclovir between days 1 and 56 of life to treat presumed herpes virus infections. Six infants were critically ill with multisystem disease, five infants had hepatic failure and underwent blood exchange transfusion, and five infants had renal failure. A mean of four (range 1 to 19) serum acyclovir concentrations per patient were measured by radioimmunoassay. Pharmacokinetic parameters were calculated from acyclovir concentrations in 46 samples from 16 patients. Measurements and main results: The pharmacokinetic disposition of acyclovirwas described as a two-compartment model. Although the ranges for acyclovir clearance and terminal elimination (t1/2β) were wide, a statistically, significant relationship was demonstrated between clearance and beta versus serum creatinine concentration. The average t1/2β for infants with serum creatinine level <1 mg/dl (88 μmol/L) was 5.0 hours, and 15.6 hours for those with serum creatinine level >1 mg/dl. Conclusions: Neonates with hepatic or renal dysfunction or young premature infants accumulate acyclovir when dosed without adjustment for organ dysfunction. Measurement of serum creatinine or creatinine clearance can be useful in the dosing of acyclovir in neonates.

UR - http://www.scopus.com/inward/record.url?scp=0025817619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025817619&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(05)81053-4

DO - 10.1016/S0022-3476(05)81053-4

M3 - Article

VL - 119

SP - 129

EP - 135

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 1 PART 1

ER -